Hikma Pharmaceuticals 

$47.75
499
+$0.00+0%Thursday 21:00

Statistics

Day High
46.68
Day Low
46.68
52W High
47.75
52W Low
31.8
Volume
1
Avg. Volume
184
Mkt Cap
11.21B
P/E Ratio
11.61
Dividend Yield
3.6%
Dividend
1.72

Upcoming

Dividends

3.6%Dividend Yield
Sep 2026
$0.76
May 2026
$0.96
Sep 2025
$0.72
May 2025
$0.96
Sep 2024
$0.64
10Y Growth
10.39%
5Y Growth
10.59%
3Y Growth
11.52%
1Y Growth
2.38%

Earnings

Aug 6Expected
Q2 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
75.82
83.76
91.7
99.63
Expected EPS
81.7608
Actual EPS
93.65328000000001

Financials

12%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
3.35BRevenue
402MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HKMPY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap49.09B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, directly competing with Hikma in the generics and branded drugs markets.
Novartis
NVS
Mkt Cap303.67B
Novartis is a large multinational pharmaceutical company with a strong presence in generic drugs through its Sandoz division, making it a direct competitor to Hikma.
Pfizer
PFE
Mkt Cap173.95B
Pfizer is a global pharmaceutical corporation with a broad portfolio that includes generic drugs, competing with Hikma in various therapeutic areas.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie, known for its significant research-based pharmaceuticals, competes with Hikma in the specialty pharmaceuticals market, particularly in areas like immunology and oncology.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes with Hikma in the development and marketing of pharmaceuticals for various therapeutic areas.
Merck
MRK
Mkt Cap368.89B
Merck & Co. is a global healthcare company that competes with Hikma in the development, manufacturing, and marketing of pharmaceuticals and vaccines.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline is a global healthcare company that competes with Hikma in the pharmaceutical and vaccines sectors, with a broad portfolio of products.
Sanofi
SNY
Mkt Cap106.24B
Sanofi is a global pharmaceutical company that competes with Hikma in the areas of generics, specialty care, and vaccines.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca is a global, science-led biopharmaceutical business that competes with Hikma in the development and commercialization of prescription medicines across multiple therapy areas.

About

Hikma Pharmaceuticals PLC is a global pharmaceutical enterprise involved in the creation, production, promotion, and distribution of a wide array of generic, branded, and licensed medicinal solutions. These offerings are presented in various dosage formats, including solid, semi-solid, liquid, and injectable forms. The company's operations are strategically structured into three core segments: Injectables, Generics, and Branded. The Injectables division specializes in providing generic injectable medications, predominantly for hospital environments. Conversely, the Generics segment is responsible for supplying oral and other non-injectable generic pharmaceuticals to the consumer retail market. The Branded unit caters to both retail and hospital clients with its proprietary generic and in-licensed products. Hikma's comprehensive product portfolio addresses a broad spectrum of medical conditions, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory ailments. The firm boasts a substantial international presence, conducting business across the United Kingdom, the United States, the Middle East, North Africa, and various European countries. Founded in 1978, the company's corporate headquarters are situated in London, United Kingdom.
Show More
CEO
Said Samih Taleb Darwazah
Employees
9500
Country
United Kingdom
ISIN
US4312881091
WKN
000A1JTM3

Listings

0 Comments

Share your thoughts

FAQs

What is Hikma Pharmaceuticals stock price today?▼
The current price of HKMPY is $47.75 USD — it has increased by +0% in the past 24 hours. Watch Hikma Pharmaceuticals stock price performance more closely on the chart.
What is Hikma Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Hikma Pharmaceuticals stocks are traded under the ticker HKMPY.
Is Hikma Pharmaceuticals stock price growing?▼
HKMPY stock has risen by +2.62% compared to the previous week, the month change is a +12.35% rise, over the last year Hikma Pharmaceuticals has showed a +13.69% increase.
What is Hikma Pharmaceuticals market cap?▼
Today Hikma Pharmaceuticals has the market capitalization of 11.21B
When is the next Hikma Pharmaceuticals earnings date?▼
Hikma Pharmaceuticals is going to release the next earnings report on February 25, 2027.
What were Hikma Pharmaceuticals earnings last quarter?▼
HKMPY earnings for the last quarter are 1.26 USD per share, whereas the estimation was 1.1 USD resulting in a +14.55% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Hikma Pharmaceuticals revenue for the last year?▼
Hikma Pharmaceuticals revenue for the last year amounts to 3.35B USD.
What is Hikma Pharmaceuticals net income for the last year?▼
HKMPY net income for the last year is 402M USD.
Does Hikma Pharmaceuticals pay dividends?▼
Yes, HKMPY dividends are paid semi-annual. The last dividend per share was 0.76 . As of today, Dividend Yield (FWD)% is 3.6%.
How many employees does Hikma Pharmaceuticals have?▼
As of November 7, 2026, the company has 9,500 employees.
In which sector is Hikma Pharmaceuticals located?▼
Hikma Pharmaceuticals operates in the Health & Wellness sector.
When did Hikma Pharmaceuticals complete a stock split?▼
Hikma Pharmaceuticals has not had any recent stock splits.
Where is Hikma Pharmaceuticals headquartered?▼
Hikma Pharmaceuticals is headquartered in London, United Kingdom.